GHRS GH Research PLC IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1855129 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-23.9%
TTM EPS YoY-5.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-21.0%
ROA-20.3%
ROIC (approx.)-86.0%
Asset turnover—
Leverage & solvency
Liabilities / assets3.0%
Debt / equity0.00x
Current ratio34.13x
Interest coverage-131.14x
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-2.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $38.77M | $35.02M | $29.82M | $20.48M | $8.55M |
| SG&A expense | $21.95M | $15.30M | $11.40M | $10.07M | $6.55M |
| Operating income | -$60.72M | -$50.31M | -$41.22M | -$30.55M | -$15.10M |
| Interest expense | $463,000 | $717,000 | $723,000 | $123,000 | $9,000 |
| Pretax income | -$48.26M | -$38.96M | -$35.59M | -$22.46M | -$9.20M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$48.26M | -$38.96M | -$35.59M | -$22.46M | -$9.20M |
| EBITDA | -$60.38M | -$50.00M | -$40.91M | -$30.51M | -$15.08M |
| EPS (basic) | -0.79 | -0.75 | -0.68 | -0.43 | -0.21 |
| EPS (diluted) | -0.79 | -0.75 | -0.68 | -0.43 | -0.21 |
| Balance sheet | |||||
| Cash & equivalents | $246.25M | $100.79M | $78.42M | $165.96M | $276.78M |
| Current assets | $285.98M | $154.22M | $164.09M | $168.54M | $279.84M |
| PP&E, netmay include right-of-use assets (IFRS) | $620,000 | $748,000 | $1.07M | $97,000 | $82,000 |
| Total assets | $288.23M | $188.27M | $226.30M | $254.36M | $279.92M |
| Current liabilities | $8.38M | $8.95M | $6.70M | $4.55M | $2.75M |
| Total liabilities | $8.53M | $9.32M | $7.33M | $4.55M | $2.75M |
| Shareholders' equity | $279.70M | $178.95M | $218.97M | $249.82M | $277.18M |
| Cash flow statement | |||||
| Operating cash flow | -$43.55M | -$42.28M | -$33.34M | -$26.20M | -$15.28M |
| Capital expenditure | $121,000 | $49,000 | $100,000 | $67,000 | $104,000 |
| Free cash flow | -$43.67M | -$42.33M | -$33.44M | -$26.27M | -$15.39M |
| Investing cash flow | $46.17M | $65.14M | -$54.10M | -$84.69M | -$104,000 |
| Financing cash flow | $139.65M | -$304,000 | -$204,000 | $0 | $286.45M |
| Depreciation & amortization | $335,000 | $315,000 | $315,000 | $47,000 | $19,000 |
| Stock-based compensation | $8.50M | $1.17M | $2.29M | $1.67M | $366,000 |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.